A study of the safety and harms of antidepressant drugs for older people: A cohort study using a large primary care database

Health Technology Assessment

Volumn 15, Issue 28, 2011, Pages 5-218

  Coupland, C A C ^a   Dhiman, P ^a   Barton, G ^b   Morriss, R ^a   Arthur, A ^a   Sach, T ^b   Hippisley Cox, J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOSULEPIN; ESCITALOPRAM; FLUOXETINE; LOFEPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADVERSE OUTCOME; AGED; ARTICLE; AUTOMUTILATION; BULLOUS SKIN DISEASE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DEPRESSION; DISEASE SEVERITY; DRUG COST; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPSY; FALLING; FEMALE; FOLLOW UP; FRACTURE; GENERAL PRACTICE; HEALTH CARE UTILIZATION; HEART INFARCTION; HUMAN; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; RISK FACTOR; SEIZURE; SUDDEN DEATH; SUICIDE; SUICIDE ATTEMPT; TRAFFIC ACCIDENT; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; UPPER GASTROINTESTINAL BLEEDING; AGE DISTRIBUTION; CAUSE OF DEATH; CLASSIFICATION; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG USE; ECONOMICS; METHODOLOGY; PRIMARY HEALTH CARE; RISK ASSESSMENT; SEX RATIO; STATISTICS; TREATMENT OUTCOME; VERY ELDERLY;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CAUSE OF DEATH; COHORT STUDIES; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; DRUG COSTS; DRUG UTILIZATION REVIEW; FEMALE; GREAT BRITAIN; HUMANS; MALE; PRIMARY HEALTH CARE; RISK ASSESSMENT; SEX DISTRIBUTION; TREATMENT OUTCOME;

EID: 80051656973     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta15280     Document Type: Article

References (189)

1. Beekman AT, Copeland JR, Prince MJ. Review of community prevalence of depression in later life. Br J Psychiatry 1999;174:307-11.
2. The NHS Information Centre Prescribing Support Unit (PSU). Prescriptions dispensed in the community. Statistics for 1998 to 2008. London: MJ Group and RPS Publishing; 2009.
3. National Institute for Health and Clinical Excellence (NICE). Depression: the treatment and management of depression in adults (update). National Clinical Practice Guideline 90. London: NICE; 2009.
4. Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev 2009; Issue 3, Art. No. CD007954.
5. Mottram PG, Wilson K, Strobl JJ. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006; 1. DOI: 10.1002/14651858.CD003491.pub2 2006.
6. Wilson K, Mottram PG, Sivananthan A, Nightingale A. Antidepressants versus placebo for the depressed elderly. Cochrane Database Syst Rev 2009;1:CD000561. DOI: 10.1002/14651858.CD000561.
7. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010;303:47-53.
8. Cadieux RJ. Antidepressant drug interactions in the elderly. Understanding the P450 system is half the battle in reducing risks. Postgrad Med 1999;106:231-2.
9. Giron MS, Fastbom J, Winblad B. Clinical trials of potential antidepressants: to what extent are the elderly represented: a review. Int J Geriatr Psychiatry 2005;20:201-17.
10. Pollock BG. Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry 1999;60(Suppl.):4-8.
11. Parikh C. Antidepressants in the elderly: challenges for study design and their interpretation. Br J Clin Pharmacol 2000;49:539-47.
12. Shah R, Uren Z, Baker A, Majeed A. Deaths from antidepressants in England and Wales 1993-1997: analysis of a new national database. Psychol Med 2001;31:1203-10.
13. Neutel CI, Patten SB. Risk of suicide attempts after benzodiazepine and/or antidepressant use. Ann Epidemiol 1997;7:568-74.
14. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292:338-43.
15. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005;330:389.
16. Hippisley-Cox J, Pringle M, Hammersley V, Crown N, Wynn A, Meal A, et al. Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care. BMJ 2001;323:666-9.
17. Monster TBM, Johnsen SP, Olsen ML, McLaughlin JK, Sorensen HT. Antidepressants and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. Am J Med 2004;117:732-7.
18. Tata LJ, West J, Smith C, Farrington P, Card T, Smeeth L, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart 2005;91:465-71.
19. Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998;351:1303-7.
20. Hubbard R, Farrington P, Smith C, Smeeth L, Tattersfield A. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003;158:77-84.
21. Ramaekers JG. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. J Clin Psychiatry 2003;64:20-9.
22. Spigset O, Hedenmalm K. Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions. Pharmacotherapy 1997;17:348-52.
23. Movig KLL, Leufkens HGM, Lenderink AW, van den Akker VGA, Hodiamont PPG, Goldschmidt HMJ, et al. Association between antidepressant drug use and hyponatraemia: a case-control study. Br J Clin Pharmacol 2002;53:363-9.
24. van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001;323:655-8.
25. de Jong JC, van den Berg PB, Tobi H, de Jong-van den Berg LT. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 2003;55:591-5.
26. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a populationbased cohort study. Arch Intern Med 2003;163:59-64.
27. Tata LJ, Fortun PJ, Hubbard RB, Smeeth L, Hawkey CJ, Smith CJ, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 2005;22:175-81.
28. Bingefors K, Isacson D, vonKnorring L, Smedby B, Wicknertz K. Antidepressant-treated patients in ambulatory care mortality during a nine-year period after first treatment. Br J Psychiatry 1996;169:647-54.
29. Ryan J, Carriere I, Ritchie K, Stewart R, Toulemonde G, Dartigues J-F, et al. Late-life depression and mortality: influence of gender and antidepressant use. Br J Psychiatry 2008;192:12-18.
30. Whang W, Kubzansky LD, Kawachi I, Rexrode KM, Kroenke CH, Glynn RJ, et al. Depression and risk of sudden cardiac death and coronary heart disease in women. Results from the Nurses' Health Study. J Am Coll Cardiol 2009;53:950-8.
31. Chen Y, Guo JJ, Li H, Wulsin L, Patel NC. Risk of cerebrovascular events associated with antidepressant use in patients with depression: a population-based, nested case-control study. Ann Pharmacother 2008;42:177-84.
32. Smoller JW, Allison M, Cochrane BB, Curb JD, Perlis RH, Robinson JG, et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative Study. Arch Intern Med 2009;169:2128-39.
33. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993;54:289-99.
34. Vassilev ZP, Chu AF, Ruck B, Adams EH, Marcus SM. Evaluation of adverse drug reactions reported to a poison control center between 2000 and 2007. Am J Health Syst Pharm 2009;66:481-7.
35. McCrone P, Dhanasiri S, Patel A. Paying the price: the cost of mental health care in England to 2026. London: King's Fund; 2008.
36. Pirmohamed M, James S, Meakin A, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-19.
37. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007;63:136-47.
38. The fourth report from the Patient Safety Observatory. Safety in doses: medication safety incidents in the NHS. National Patient Safety Agency; 2007.
39. Sach T, Barton GR, Jenkinson C, Doherty M, Avery A, Muir KR. Comparing cost-utility estimates: Does the choice of E D or S D matter? Med Care 2009;47:889-94.
40. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 1995;51:228-35.
41. Whitaker H. The self controlled case series method. BMJ 2008;337:a1069.
42. Hippisley-Cox J, Vinogradova Y, Coupland C, Pringle M. Comparison of key practice characteristics between general practices in England and Wales and general practices in the QResearch database. Report to the Health and Social Care Information Centre. Nottingham: University of Nottingham; 2005.
43. Hippisley-Cox J, Pringle M. Prevalence, care and outcomes for patients with diet controlled diabetes in general practice: cross-sectional survey. Lancet 2004;364:423-5.
44. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all-cause mortality in patients with ischaemic heart disease: nested case control analysis. BMJ 2005;330:1059-63.
45. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
46. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients on Cox 2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;366:1366-74.
47. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;331:1310-16.
48. World Health Organization (WHO). Manual of the international statistical classification of diseases, injuries and causes of death. Volume 1. Geneva: WHO: 1997.
49. World Health Organization (WHO). World Health Organization:International Statistical Classification of Disease and Related Health Problems. Tenth Revision (ICD-10). Geneva: WHO: 1992.
50. Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007;334:242.
51. Gibson JE, Hubbard RB, Smith CJP, Tata LJ, Britton JR, Fogarty AW. Use of self-controlled analytical techniques to assess the association between use of prescription medications and the risk of motor vehicle crashes. Am J Epidemiol 2009;169:761-8.
52. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 54, September 2007. London: BMA and RPS; 2007.
53. Townsend P, Phillimore P, Beattie A. Health and deprivation: inequality and the north. London: Croom Helm; 1988.
54. Kaye JA, Jick H. Epidemiology of lower limb fractures in general practice in the United Kingdom. Inj Prev 2004;10:368-74.
55. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319:1492-5.
56. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 1996;143:1165-73.
57. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the selfcontrolled case series method. Stat Med 2006;25:1768-97.
58. Musonda P, Farrington CP, Whitaker HJ. Sample sizes for self-controlled case series studies. Stat Med 2006;25:2618-31.
59. National Institute of Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2008.
60. Health and Social Care Information Centre Prescribing Support Unit (PSU). Prescription cost analysis: England 2008. The NHS Information Centre, 2009. URL: www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-2008.
61. HM Treasury. The Green Book: appraisal and evaluation in central government. London: The Stationery Office; 2003.
62. Curtis L. Unit costs of health and social care. The University of Kent: Personal Social Services Research Unit; 2008.
63. Department of Health. NHS reference costs 2006-07. London: Department of Health; 2008.
64. Briggs AH, Sculpher MJ, Claxton K. Decision modelling for health economic evaluation. New York: Oxford University Press; 2006.
65. Barton GR, Briggs AH, Fenwick EA. Optimal cost-effective decisions: the role of the costeffectiveness acceptability curve (CEAC), cost-effectiveness acceptability frontier (CEAF) and expected value of perfect information (EVPI). Value Health 2008;11:886-97.
66. Drummond MF, Sculpher MJ, Torrance GW, O Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes 3rd edn. New York, NY: Oxford University Press; 2005.
67. UK BEAM Trial Team. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care. BMJ 2004;329:1381.
68. Furukawa TA, McGuire H, Barbui C. Low dosage tricyclic antidepressants for depression. Cochrane Database Syst Rev 2003;3:CD003197. DOI: 10.1002/14651858.CD0031972003.
69. Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res 2002;53:849-57.
70. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006;27:2763-74.
71. Hippisley-Cox J, Fielding K, Pringle M. Depression as a risk factor for ischaemic heart disease in men: population based case-control study. BMJ 1998;316:1714-19.
72. Empana JP, Jouven X, Lemaitre RN, Sotoodehnia N, Rea T, Raghunathan TE, et al. Clinical depression and risk of out-of-hospital cardiac arrest. Arch Intern Med 2006;166:195-200.
73. Maidment R, Livingston G, Katona C. Just keep taking the tablets: adherence to antidepressant treatment in older people in primary care. Int J Geriatr Psychiatry 2002;17:752-7.
74. Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006;163:101-8.
75. Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 2006;10(38).
76. Haukka J, Arffman M, Partonen T, Sihvo S, Elovainio M, Tiihonen J, et al. Antidepressant use and mortality in Finland: a register-linkage study from a nationwide cohort. Eur J Clin Pharmacol 2009;65:715-20.
77. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006;63:1358-67.
78. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000;108:2-8.
79. Glassman AH, O Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-9.
80. Carney RM, Freedland KE, Steinmeyer B, Blumenthal JA, Berkman LF, Watkins LL, et al. Depression and five year survival following acute myocardial infarction: a prospective study. J Affect Disord 2008;109:133-8.
81. Krantz DS, Whittaker KS, Francis JL, Rutledge T, Johnson BD, Barrow G, et al. Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease: outcomes from the Women's Ischemia Syndrome Evaluation (WISE) study. Heart 2009;95:1901-6.
82. Mackay FR, Dunn NR, Martin RM, Pearce GL, Freemantle SN, Mann RD. Newer antidepressants: a comparison of tolerability in general practice. Br J Gen Pract 1999;49:892-6.
83. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004;75:234-41.
84. Martinez C, Assimes TL, Mines D, Dell Aniello S, Suissa S. Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. BMJ 2010;340:c249.
85. Sherwood A, Blumenthal JA, Trivedi R, Johnson KS, O Connor CM, Adams KF, et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med 2007;167:367-73.
86. Xiong GL, Jiang W, Clare R, Shaw LK, Smith PK, Mahaffey KW, et al. Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. Am J Cardiol 2006;98:42-7.
87. Office for National Statistics (ONS). Deaths related to drug poisoning in England and Wales, 2002-06. Health Stat Q 2007;36:66-72.
88. Abrams RC, Leon AC, Tardiff K, Marzuk PM, Li CS, Galea S. Antidepressant use in elderly suicide victims in New York City: an analysis of 255 cases. J Clin Psychiatry 2009;70:312-17.
89. Isacsson G, Bergman U, Rich CL. Antidepressants, depression and suicide: an analysis of the San Diego study. J Affect Disord 1994;32:277-86.
90. Jonasson B, Jonasson U, Saldeen T. Among fatal poisonings dextropropoxyphene predominates in younger people, antidepressants in the middle aged and sedatives in the elderly. J Forensic Sci 2000;45:7-10.
91. Harwood DMJ, Hawton K, Hope T, Jacoby R. Suicide in older people: mode of death, demographic factors, and medical contact before death. Int J Geriatr Psychiatry 2000;15:736-43.
92. Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. Br Med J 1987;295:1021-4.
93. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995;310:221-4.
94. Montgomery SA, Baldwin D, Green M. Why do amitriptyline and dothiepin appear to be so dangerous in overdose? Acta Psychiatr Scand 1989;80:47-53.
95. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002;325:1332-3.
96. Bauer M, Monz BU, Montejo AL, Quail D, Dantchev N, Dernyttenaere K, et al. Prescribing patterns of antidepressants in Europe: results from the factors influencing depression endpoints research (FINDER) study. Eur Psychiatry 2008;23:66-73.
97. Flanagan RJ. Fatal toxicity of drugs used in psychiatry. Human Psychopharmacol Clin Exp 2008;23:43-51.
98. Tournier M, Grolleau A, Cougnard A, Verdoux H, Molimard M. The prognostic impact of psychotropic drugs in intentional drug overdose. Pharmacopsychiatry 2009;42:51-6.
99. Carlsten A, Waern M, Ekedahl A, Ranstam J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf 2001;10:525-30.
100. Grunebaum MF, Ellis SP, Li SH, Oquendo MA, Mann JJ. Antidepressants and suicide risk in the United States, 1985-1999. J Clin Psychiatry 2004;65:1456-62.
101. Morgan OW, Griffiths C, Majeed A. Association between mortality from suicide in England and antidepressant prescribing: an ecological study. BMC Public Health 2004;4:63.
102. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005;62:165-72.
103. Reseland S, Bray I, Gunnell D. Relationship between antidepressant sales and secular trends in suicide rates in the Nordic countries. Br J Psychiatry 2006;188:354-8.
104. Nakagawa A, Grunebaum MF, Ellis SP, Oquendo MA, Kashima H, Gibbons RD, et al. Association of suicide and antidepressant prescription rates in Japan, 1999-2003. J Clin Psychiatry 2007;68:908-16.
105. Ludwig J, Marcotte DE, Norberg K. Anti-depressants and suicide. J Health Econ 2009;28:659-76.
106. Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P. Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ 2003;326:1008.
107. Søndergård L, Kvist K, Lopez AG, Andersen PK, Kessing LV. Temporal changes in suicide rates for persons treated and not treated with antidepressants in Denmark during 1995-1999. Acta Psychiatr Scand 2006;114:168-76.
108. Nettelbladt P, Mattisson C, Bogren M, Holmqvist M. Suicide rates in the Lundby cohort before and after the introduction of tricyclic antidepressant drugs. Arch Suicide Res 2007;11:57-67.
109. Hall WD, Lucke J. How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality? Aust N Z J Psychiatry 2006;40:941-50.
110. Erlangsen A, Canudas-Romo V, Conwell Y. Increased use of antidepressants and decreasing suicide rates: a population-based study using Danish register data. J Epidemiol Community Health 2008;62:448-54.
111. Morgan O, Griffiths C, Majeed A. Antidepressant prescribing and changes in antidepressant poisoning mortality and suicide in England, 1993-2004. J Public Health 2008;30:60-8.
112. Kalmar S, Szanto K, Rihmer Z, Mazumdar S, Harrison K, Mann JJ. Antidepressant prescription and suicide rates: effect of age and gender. Suicide Life Threat Behav 2008;38:363-74.
113. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000;57:311-17.
114. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003;160:790-2.
115. Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006;26:203-7.
116. Simon GE, VonKorff M. Suicide mortality among patients treated for depression in an insured population. Am J Epidemiol 1998;147:155-60.
117. Simon GE. How can we know whether antidepressants increase suicide risk? Am J Psychiatry 2006;163:1861-3.
118. Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006;163:813-21.
119. Szanto K, Mulsant BH, Houck P, Dew MA, Reynolds CF III. Occurrence and course of suicidality during short-term treatment of late-life depression. Arch Gen Psychiatry 2003;60:610-17.
120. Rahme E, Dasgupta K, Turecki G, Nedjar H, Galbaud du Fort G. Risks of suicide and poisoning among elderly patients prescribed selective serotonin reuptake inhibitors: a retrospective cohort study. J Clin Psychiatry 2008;69:349-57.
121. Perlis RH, Beasley Jr CM, Wines Jr JD, Tamura RN, Cusin C, Shear D, et al. Treatmentassociated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom 2007;76:40-6.
122. Perroud N, Uher R, Marusic A, Rietschel M, Mors O, Henigsberg N, et al. Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. BMC Med 2009;7:60.
123. Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Arch Gen Psychiatry 2006;63:865-72.
124. Bateman DN, Chick J, Good AM, Kelly CA, Masterton G. Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose? Eur J Clin Pharmacol 2004;60:221-4.
125. Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009;339:b2880.
126. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005;330:385.
127. Beasley CM Jr, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH Jr, Heiligenstein JH, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991;303:685-92.
128. Tauscher-Wisniewski S, Disch D, Plewes J, Ball S, Beasley CM. Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder. Psychol Med 2007;37:1585-93.
129. Vanderburg DG, Batzar E, Fogel I, Kremer CM. A pooled analysis of suicidality in doubleblind, placebo-controlled studies of sertraline in adults. J Clin Psychiatry 2009;70:674-83.
130. Acharya N, Rosen AS, Polzer JP, D Souza DN, Perahia DG, Cavazzoni PA, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol 2006;26:587-94.
131. Mulder RT, Joyce PR, Frampton CMA, Luty SE. Antidepressant treatment is associated with a reduction in suicidal ideation and suicide attempts. Acta Psychiatr Scand 2008;118:116-22.
132. Valuck RJ, Orton HD, Libby AM. Antidepressant discontinuation and risk of suicide attempt: a retrospective, nested case-control study. J Clin Psychiatry 2009;70:1069-77.
133. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006;163:41-7.
134. Didham RC, McConnell DW, Blair HJ, Reith DM. Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication. Br J Clin Pharmacol 2005;60:519-525.
135. Oquendo MA, Kamali M, Ellis SP, Grunebaum MF, Malone KM, Brodsky BS, et al. Adequacy of antidepressant treatment after discharge and the occurrence of suicidal acts in major depression: a prospective study. Am J Psychiatry 2002;159:1746-51.
136. Taylor DM, Cameron PA, Eddey D. Recurrent overdose: patient characteristics, habits, and outcomes. J Accid Emerg Med 1998;15:257-61.
137. Bernal M, Haro JM, Bernert S, Brugha T, de Graaf R, Bruffaerts R, et al. Risk factors for suicidality in Europe: results from the ESEMED study. J Affect Disord 2007;101:27-34.
138. Hawton K, Bergen H, Casey D, Simkin S, Palmer B, Cooper J, et al. Self-harm in England: a tale of three cities. Multicentre study of self-harm. Soc Psychiatry Psychiatr Epidemiol 2007;42:513-21.
139. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003;108:32-6.
140. Schlienger RG, Fischer LM, Jick H, Meier CR. Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Safety 2004;27:1157-65.
141. Blanchette CM, Simoni-Wastila L, Zuckerman IH, Stuart B. A secondary analysis of a duration response association between selective serotonin reuptake inhibitor use and the risk of acute myocardial infarction in the aging population. Ann Epidemiol 2008;18:316-21.
142. Starkstein SE, Mizrahi R, Power BD. Antidepressant therapy in post-stroke depression. Expert Opin Pharmacother 2008;9:1291-8.
143. Bak S, Tsiropoulos I, Kjaersgaard JO, Andersen M, Mellerup E, Hallas J, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 2002;33:1465-73.
144. Chen Y, Guo JJ, Patel NC. Hemorrhagic stroke associated with antidepressant use in patients with depression: does degree of serotonin reuptake inhibition matter? Pharmacoepidemiology Drug Saf 2009;18:196-202.
145. Salaycik KJ, Kelly-Hayes M, Beiser A, Nguyen AH, Brady SM, Kase CS, et al. Depressive symptoms and risk of stroke the Framingham Study. Stroke 2007;38:16-21.
146. Kharofa J, Sekar P, Haverbusch M, Moomaw C, Flaherty M, Kissela B, et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke 2007;38:3049-51.
147. de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol 2000;50:43-7.
148. Darowski A, Chambers SACF, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging 2009;26:381-94.
149. Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009;169:1952-60.
150. Ensrud KE, Blackwell TL, Mangione CM, Bowman PJ, Whooley MA, Bauer DC, et al. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 2002;50:1629-37.
151. Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998;339:875-82.
152. Kerse N, Flicker L, Pfaff JJ, Draper B, Lautenschlager NT, Sim M, et al. Falls, depression and antidepressants in later life: a large primary care appraisal. PLoS ONE 2008;3:e2423.
153. Kallin K, Gustafson Y, Sandman P-O, Karlsson S. Drugs and falls in older people in geriatric care settings. Aging Clin Exp Res 2004;16:270-6.
154. Arfken CL, Wilson JG, Aronson SM. Retrospective review of selective serotonin reuptake inhibitors and falling in older nursing home residents. Int Psychogeriatr 2001;13:85-91.
155. Ziere G, Dieleman JP, van der Cammen TJM, Hofman A, Pols HAP, Stricker BHC. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008;28:411-17.
156. Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007;167:188-94.
157. Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int 2008;82:92-101.
158. Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007;167:1246-51.
159. Diem SJ, Blackwell TL, Stone KL, Yaffe K, Cauley JA, Whooley MA, et al. Depressive symptoms and rates of bone loss at the hip in older women. J Am Geriatr Soc 2007;55:824-31.
160. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006:1; CD003491.
161. Barbui C, Andretta M, De Vitis G, Rossi E, D Arienzo F, Mezzalira L, et al. Antidepressant drug prescription and risk of abnormal bleeding: a case-control study. J Clin Psychopharmacol 2009;29:33-8.
162. de Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008;65:795-803.
163. Vidal X, Ibanez L, Vendrell L, Conforti A, Laporte JR. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf 2008;31:159-68.
164. Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract 2005;59:1435-40.
165. Gidal BE, French JA, Grossman P, Le Teuff G. Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 2009;72:419-25.
166. Hesdorffer DC, Hauser WA, Annegers JF, Cascino G. Major depression is a risk factor for seizures in older adults. Ann Neurol 2000;47:246-9.
167. Kumlien E, Lundberg PO. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure 2010;19:69-73.
168. Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002;25:91-110.
169. Wedin GP, Oderda GM, Klein-Schwartz W, Gorman RL. Relative toxicity of cyclic antidepressants. Ann Emerg Med 1986;15:797-804.
170. Buckley NA, Dawson AH, White IM, Henry DA. Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet 1994;343:159-62.
171. Grundemar L, Wohlfart B, Lagerstedt C, Bengtsson F, Eklundh G. Symptoms and signs of severe citalopram overdose. Lancet 1997;349:1602.
172. Kelly CA, Dhaun N, Laing WJ, Strachan FE, Good AM, Bateman DN. Comparative toxicity of citalopram and the newer antidepressants after overdose. Clin Toxicol 2004;42:67-71.
173. Ojemann LM, Friel PN, Trejo WJ, Dudley DL. Effect of doxepin on seizure frequency in depressed epileptic patients. Neurology 1983;33:646.
174. Favale E, Rubino V, Mainardi P, Lunardi G, Albano C. Anticonvulsant effect of fluoxetine in humans. Neurology 1995;45:1926-7.
175. Hu PS, Trumble DA, Foley DJ, Eberhard JW, Wallace RB. Crash risks of older drivers: a panel data analysis. Accid Anal Prev 1998;30:569-81.
176. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992;136:873-83.
177. Leveille S, Buchner D, Koepsell T, McCloskey L, Wolf M, Wagner E. Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology 1994;5:591-8.
178. Bramness JG, Skurtveit S, Neutel CI, Morland J, Engeland A. Minor increase in risk of road traffic accidents after prescriptions of antidepressants: a study of population registry data in Norway. J Clin Psychiatry 2008;69:1099-103.
179. Movig KLL, Mathijssen MPM, Nagel PHA, van Egmond T, de Gier JJ, Leufkens HGM, et al. Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev 2004;36:631-6.
180. Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998;352:1331-6.
181. Wester K, Jonsson AK, Spigset O, Druid H, Hagg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 2008;65:573-9.
182. Degner D, Grohmann R, Kropp S, Ruther E, Bender S, Engel RR, et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004;37(Suppl. 1):39-45.
183. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44.
184. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis 2008;52:144-53.
185. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 2006;40:1618-22.
186. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008;149:734-50.
187. Movig KLL, Leufkens HGM, Lenderink AW, Egberts ACG. Serotonergic antidepressants associated with an increased risk for hyponatraemia in the elderly. Eur J Clin Pharmacol 2002;58:143-8.
188. Kirby D, Harrigan S, Ames D. Hyponatraemia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. Int J Geriatr Psychiatry 2002;17:231-7.
189. National Collaborating Centre for Mental Health. Depression: the treatment and management of depression in adults. National Clinical Practice Guideline 90. London: NICE; 2009.